Intermediate Risk Clinical Trials in Paris
2 recruitingParis, France
Showing 1–2 of 2 trials
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled94 locationsNCT06510374
Recruiting
Phase 3
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
Thyroid CancerIntermediate Risk
Centre Francois Baclesse476 enrolled29 locationsNCT04290663